Good to get a different perspective from you @Chagsy and @Invmum. As I said it's too easy to fall in love with a stock, and suffer confirmation bias, and only see the positives.

The recent study you quote was the pilot study done a year ago, and is not necessarily the current set up of the product. Management have said that they have used that initial data to fine tune the algorithms, and we will have to see the results of the next clinical trials. Time will tell.

I think the big game changer will be the 2nd Gen device, which is being developed concurrently with the 1st Gen device. This is the portable machine for use in ambulances, and according to management the aim is to allow treatment "in the driveway" during what is known as the golden hour for stroke patients. Thus, its use is not just to determine which facility to transport the patient to, but to actually treat the patient on the spot during the most critical time. Obviously you would want to be sure that the correct type of stroke has been diagnosed, as the treatments are different, and potentially life threatening if wrong. But that's what the upcoming trials are about.

I realise that the approval process is slow, expensive and has a poor success rate, but Dr Ron Weinberger has been through this before with Nanosonics, and has surrounded himself with a very impressive senior team.

Innovative medical companies are almost always high risk investments, and not for everyone, but with risk comes reward, if successful.

Appreciate your comments.
 

Ann: 1st Gen Device Successfully Manufactured & Ready for Testing.

Another milestone successfully reached.

Article in today's Fin Review:

"EMVision launches portable scanner to diagnose brain trauma

Carrie LaFrenzSenior reporter
Aug 10, 2021 – 6.00am

ASX- listed EMVision Medical Devices is launching a portable commercial scanner that snaps an image of a patient’s brain by the bedside to speed up diagnosis of strokes and other traumatic brain injuries.

The first generation device has been assembled and is targeted for use in intensive care units, stroke and neurology wards and emergency departments. The device was developed using intellectual property from over a decade of research and development at The University of Queensland.


EMVision CEO Dr Ron Weinberger (L), and co-founder and executive director, Scott Kirkland, with their first portable brain scanner model, intended for commercialisation. Dominic Lorrimer

The Brisbane-based medical technology start-up is headed by the former Nanosonics chief executive Ron Weinberger, who says the product is a “game changer” for how practitioners diagnose and care for patients.

Demand for existing ways of detecting brain trauma or brain changes before treatment, such as CT and MRI scans, often exceeds supply in hospitals, making it difficult to get patients scanned, Dr Weinberger told The Australian Financial Review.

“Today, there is not any way for getting patients scanned at the bedside or in the home. We are solving this problem.”

Dr Weinberger likened to scanner to an ultrasound for the brain: the patient puts a swimming cap-like covering on their head, it takes seconds for the scan to work, and a few minutes to create rapid images.

The device aims to speed up decision-making, particularly within the critical “golden hour” after a stroke. The technology has the potential to improve survival rates and quality of life after strokes.

“We started with stroke because of the huge health burden, which is one of the most significant diseases in the world today,” Dr Weinberger said."

Difficult to put a value on this Company, but all the bricks have been put in place, we have a very competent management team, enough funds on hand,, and well down the track of gaining approval for the scanner. If successful, the machine will  be a terrific medical breakthrough.

I've held this stock for some time now, and have been impressed with how management has successfully charted the Company's course, without putting a foot wrong. Too easy to fall in love with a stock, but this is definitely my current favourite ASX stock at the moment.